Two-year follow-up in 150 consecutive cases with normal dopamine transporter imaging

Background and aims Functional pre-synaptic dopamine brain imaging is generally abnormal when parkinsonism is degenerative (such as in idiopathic Parkinson's disease) and normal in patients with non-degenerative movement disorder (such as essential tremor). However, some patients diagnosed as early Parkinson's disease have normal presynaptic dopamine imaging. Follow-up of patients with normal imaging should help determine whether such patients truly have degenerative parkinsonism (and therefore represent false negative imaging results), or emerge as cases of non-degenerative parkinsonism (and therefore represent initial clinical over-diagnosis of Parkinson's disease). Methods and results One hundred and fifty cases with normal 123I-FP-CIT SPECT undertaken during routine care over a 3-year period were reviewed 2.4 years (interquartile range, 2.2–3.1 years) after SPECT. Diagnosis after follow-up was non-degenerative parkinsonism or tremor in 146 (97%), who did not progress clinically, and degenerative parkinsonism in four (3%), in whom clinicial progression was noted. Anti-Parkinson therapy was used in 36, and withdrawn in 27 with no deterioration in 25. Patients strictly fulfilling Brain Bank criteria (part 1) were more likely to undergo a trial of anti-Parkinson therapy (P<0.05) but were no more likely to maintain or respond to anti-Parkinson therapy than those not fulfilling criteria. Conclusion The clinical profile and therapy response during follow-up of patients with normal presynaptic dopamine imaging supports the diagnosis of a non-degenerative movement disorder in nearly all cases.

[1]  S. Aalto,et al.  Striatal subregional 6‐[18F]fluoro‐L‐dopa uptake in early Parkinson's disease: A two‐year follow‐up study , 2006, Movement disorders : official journal of the Movement Disorder Society.

[2]  P. Stanzione,et al.  123I-FP-CIT in progressive supranuclear palsy and in Parkinson's disease: a SPECT semiquantitative study , 2006, Nuclear medicine communications.

[3]  Orazio Schillaci,et al.  123I-FP-CIT semi-quantitative SPECT detects preclinical bilateral dopaminergic deficit in early Parkinson's disease with unilateral symptoms , 2005, Nuclear medicine communications.

[4]  P. M. Kemp,et al.  Imaging the dopaminergic system in suspected parkinsonism, drug induced movement disorders, and Lewy body dementia , 2005, Nuclear medicine communications.

[5]  P. Morrish The meaning of negative DAT SPECT and F‐Dopa PET scans in patients with clinical Parkinson's disease , 2005, Movement disorders : official journal of the Movement Disorder Society.

[6]  C. Tanner,et al.  Levodopa and the progression of Parkinson's disease. , 2004, The New England journal of medicine.

[7]  E. Tolosa,et al.  Impact of dopamine transporter SPECT using 123I‐Ioflupane on diagnosis and management of patients with clinically uncertain parkinsonian syndromes , 2004, Movement disorders : official journal of the Movement Disorder Society.

[8]  David Oakes,et al.  (123I) beta-CIT and single-photon emission computed tomographic imaging vs clinical evaluation in Parkinsonian syndrome: unmasking an early diagnosis. , 2004, Archives of neurology.

[9]  Regina Katzenschlager,et al.  Unclassifiable parkinsonism in two European tertiary referral centres for movement disorders , 2003, Movement disorders : official journal of the Movement Disorder Society.

[10]  Oliver Pogarell,et al.  Prospective study of presynaptic dopaminergic imaging in patients with mild parkinsonism and tremor disorders: Part 1. Baseline and 3‐month observations , 2003, Movement disorders : official journal of the Movement Disorder Society.

[11]  Claude Nahmias,et al.  Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL‐PET study , 2003, Annals of neurology.

[12]  J. C. Stoof,et al.  [123I]β-CIT SPECT is a useful method for monitoring dopaminergic degeneration in early stage Parkinson’s disease , 2003, Journal of neurology, neurosurgery, and psychiatry.

[13]  L. Friberg,et al.  Clinical impact of diagnostic SPET investigations with a dopamine re-uptake ligand , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[14]  Z Walker,et al.  Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand , 2002, Journal of neurology, neurosurgery, and psychiatry.

[15]  J. Seibyl,et al.  [123I]β-CIT SPECT imaging assessment of the rate of Parkinson’s disease progression , 2001, Neurology.

[16]  Andrew J. Lees,et al.  Improved accuracy of clinical diagnosis of Lewy body Parkinson’s disease , 2001, Neurology.

[17]  H. Berendse,et al.  Subclinical dopaminergic dysfunction in asymptomatic Parkinson's disease patients' relatives with a decreased sense of smell , 2001, Annals of neurology.

[18]  Jan Booij,et al.  The clinical benefit of imaging striatal dopamine transporters with [123I]FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism , 2001, European Journal of Nuclear Medicine.

[19]  N. Quinn,et al.  A multicenter assessment of dopamine transporter imaging with DOPASCAN/SPECT in parkinsonism , 2000, Neurology.

[20]  D J Wyper,et al.  Correlation of Parkinson's disease severity and duration with 123I‐FP‐CIT SPECT striatal uptake , 2000, Movement disorders : official journal of the Movement Disorder Society.

[21]  J. Rinne,et al.  Progression in Parkinson's disease: A positron emission tomography study with a dopamine transporter ligand [18F]CFT , 2000, Annals of neurology.

[22]  S. Gacinovic,et al.  Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]‐FP‐CIT SPECT imaging: The [123I]‐FP‐CIT study group , 2000, Movement disorders : official journal of the Movement Disorder Society.

[23]  J. Jankovic,et al.  The evolution of diagnosis in early Parkinson disease. Parkinson Study Group. , 2000, Archives of neurology.

[24]  P. Hobson,et al.  Accuracy of diagnosis in patients with presumed Parkinson's disease. , 1999, Age and ageing.

[25]  J. P. Seibyl,et al.  [sup 123 I] beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease , 1996, Neurology.

[26]  J. Hughes,et al.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. , 1992, Journal of neurology, neurosurgery, and psychiatry.

[27]  W. Gibb,et al.  THE SIGNIFICANCE OF THE LEWY BODY IN THE DIAGNOSIS OF IDIOPATHIC PARKINSON'S DISEASE , 1989, Neuropathology and applied neurobiology.

[28]  J. Talairach,et al.  Co-Planar Stereotaxic Atlas of the Human Brain: 3-Dimensional Proportional System: An Approach to Cerebral Imaging , 1988 .

[29]  J. Booij,et al.  Practical benefit of [123I]FP-CIT SPET in the demonstration of the dopaminergic deficit in Parkinson's disease , 2005, European Journal of Nuclear Medicine.

[30]  Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. , 2002, JAMA.

[31]  J. Booij,et al.  [123I]FP-CIT SPECT is a useful method to monitor the rate of dopaminergic degeneration in early-stage Parkinson's disease , 2001, Journal of Neural Transmission.